NCT05384509
(COVID-19) Longitudinal Neutralizing Antibody Titers in Cancer Patients Receiving Different Anti-caner Therapies
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
Notable Primary and study completion dates pushed to Feb 28, 2025v3 Show 4 more changesShow less
- Eligibility criteria shortened, about 10 words
- Primary endpoints revised (8)
- Secondary endpoints revised (8)
- Study description expanded, about 22 words
- Notable Primary completion date: Nov 30, 2022 to Jul 30, 2023v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
COVID-19 N Ab trends among different subgroups (anti-cancer therapies)
Timeframe: 3 month
COVID-19 S Ab trends among different subgroups (anti-cancer therapies)
Timeframe: 3 month
Secondary (2)
COVID-19 N Ab trends among different baseline PhenoAge scores
COVID-19 S Ab trends among different baseline PhenoAge scores
Arms and interventions
Chemotherapy
Cancer Patients underwent chemotherapy
Targeted therapy
Patients underwent targeted therapy
Immunotherapy
Patients underwent immunotherapy
Disease-free
Cancer patients have been disease-free for ≥ 6 months group
Diagnostic tests: solid organ malignancies treatment
Sites
1 site in 1 country
- TuCheng HospitalNew Taipei City, Taiwan